Phase 2a clinical trial in nonsense mutation hemophilia A and hemophilia B initiated

Links shared publicly online about this topic.

1,648
total visits

Phase 2a clinical trial in nonsense mutation hemophilia A and hemophilia B initiated

PTC Therapeutics, Inc. (PTC) today announced it is expanding the development of ataluren, an investigational new drug, to a third indication with the initiation of a Phase 2a clinical trial in nonsense mutation hemophilia A (nmHA) and hemophilia B (nmHB).

View full resource at news-medical.net

Tags: Hemophilia, Drug, Clinical Trial, Oncology